[PlGF and sFlt-1--diagnostic significance in preeclampsia prediction in pregnant women with gestational and chronic hypertension].
Preeclampsia (PE) is characterized with hypertension and proteinuria after 20 gestational weeks. and is the major reason for maternal and fetal mortality during pregnancy. Etiology of PE is still unclear. Clinical manifestation is connected to high levels of circulated anti-angiogenic proteins such as soluble Fms-like tyrosine kinase 1 (sFlt1) and soluble endolgin (sEng). Furthermore PE leads to low serum levels of Placental growth factor (PIGF). The change of these serum levels appears before clinical manifestation, which makes them useful for screening of pregnant women with high risk of PE. This opportunity for prediction of PE would significantly lower the mortality caused by PE. We measure serum sFlt-1 and PIGF levels in pregnant women with normal and pathological pregnancy including gestational and chronic hypertension without PE. Population included 23 pregnant women during a period of two years. Comparison between the groups was made with parametric Student's test. A level of p < 0.05 was accepted as statistically significant. Eight women were with PE (one of them with chronic hypertension). Six pregnant women were with isolated hypertension (four with chronic and 2 with gestational hypertension). Nine pregnant women were with normal pregnancy. Serum sFlt-1 and PIGF levels showed significant differences in pregnant women in between 25th and 28th gestational weeks: a) for sFlt-1--in PE (4859.88 pg/ml) and normal pregnancy (3125.53 pg/ml)--p = 0.0002 or isolated hypertension (2791.40 pg/ml)--p = 0.0054 and b) for PIGF--in PE (206.63 pg/ml) and normal pregnancy (667.87 pg/ml)--p = 0.0011 or isolated hypertension (560.20 pg/ml)--p =0.0125. Our study shows that serum sFlt-1 and PIGF levels significantly changes during pregnancy and before clinical manifestation of PE (minimum in 15.5 gestational weeks).